Core Viewpoint - The strategic cooperation agreement between Huajian Medical and Chuangsheng Group-B marks a significant milestone in the integration of technology and finance, focusing on the tokenization of innovative drug pipeline assets valued at over $1.5 billion [1] Group 1: Strategic Cooperation - Huajian Medical and its subsidiaries ETHK Inc and ETHK HOLDINGS LIMITED have entered into a strategic cooperation agreement with Chuangsheng Group-B and its subsidiary Transcenta Oncology Inc. [1] - The agreement involves the integration of six core innovative drug pipeline assets into Transcenta Oncology Inc. [1] Group 2: Asset Valuation and Technology Solutions - The total valuation of the integrated assets exceeds $1.5 billion, representing cutting-edge research directions and high technical barriers in the global oncology treatment field [1] - The group will provide a comprehensive technical solution covering digital initiation, trusted on-chain processes, compliant issuance, and liquidity connection for these pipeline assets [1] Group 3: Market Impact - This cooperation signifies the official launch of high-value innovative drug intellectual property assets in the capital market in the form of RWA, highlighting a milestone event in the deep integration of technology and finance [1]
华检医疗(01931.HK)与创胜集团(06628.HK)签署涉15亿美元创新药管线资产RWA代币化的战略合作协议